-
Blog
Medicare presses forward with drug price setting
09.18.2023
In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting under last year's Inflation Reduction Act.
-
Blog
Mohit Manrao Talks Small-Molecule Penalty, Eliminating Cancer as a Cause of Death, and More
09.15.2023
The small-molecule penalty "doesn't create the right incentives for where we want to go with the Cancer Moonshot or driving cures," Mohit reflected.
-
Video
-
Statement
Incubate releases video explainer on small molecule penalty
09.13.2023
Incubate released a video explaining how the small molecule penalty in recently passed legislation will negatively impact medical research and innovation.
-
Statement
Life sciences investors react to first 10 drugs selected for government price controls
08.29.2023
Executive Director John Stanford issued a statement in response.
-
Comment
Incubate Comment in Response to NIH Technology Transfer Workshop
08.25.2023
Incubate submitted this comment on August 18, 2023.
-
Statement
New legislation would spread the disease of price controls to more treatments and cures
07.26.2023
Incubate Coalition executive director John Stanford issued the following statement in response to the introduction of the Lowering Drug Costs for American Families Act:
-
Comment
Incubate Submits Comment in Response to Draft Legislation to Reauthorize PAHPA
07.10.2023
Incubate recently submitted comment in response to the Senate HELP Committee’s draft legislation to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).
-
Statement
CMS’ Final Guidance on Medicare Drug Price Negotiation Program Offers Some Clarity, But Misses Opportunity to Address the Small Molecule Penalty
07.06.2023
Executive Director of Incubate, John Stanford, issued the following statement regarding the release of the Centers for Medicare and Medicaid Services’ (CMS) final guidance on the Medicare Drug Price Negotiation Program.
-
Blog
Stakeholder Voices Grow Louder on Harmful “Small Molecule Penalty”
06.29.2023
The month of June saw a flurry of activity by investors, manufacturers, patient advocates, and the scientific community who continue to express their concern that legislation passed by Congress last year will discourage R&D for small molecule medicines.
-
Infographic
Resources
